Moving a preclinical asset towards the clinic

TheraCryf's lead programme, an orexin-1 receptor antagonist intended to treat addiction, has spent the past year in late-stage preclinical work. The company now says it is approaching regulatory submissions for first-in-human studies. This article looks at what has been completed, what remains and how the company is funding the next steps.

What TheraCryf does

TheraCryf (LSE:TCF) is an AIM-quoted biotechnology company developing medicines for neuropsychiatric conditions. Its lead asset, referred to as Ox-1, targets the orexin-1 receptor and is being developed for addiction. The company also has a dopamine transporter (DAT) modulator programme aimed at fatigue conditions and a legacy oncology programme, SFX-01, in glioblastoma. It has said it is holding partnering discussions to maximise Shareholder value. Its stated focus for the current year is to bring Ox-1 to clinical readiness, which it describes as delivering key value inflection points.

Progress reported on 28 September 2026

On 28 September 2026, TheraCryf published final results for the year ended 31 March 2026. The company reported that 10.6kg of drug substance had been manufactured for toxicology studies and a final formulation selected. In GLP toxicology work, it said first-species data indicated "a wide Margin of safety" and that a second-species study had started on schedule with top-line data "again demonstrating a wide safety margin". After the year end, it completed Good Manufacturing Practice manufacture of 2.57kg of Ox-1 drug substance "suitable for administration to humans", ahead of schedule.

The next milestones, according to the company, are a regulatory data submission in Australia, an ethics submission and approvals for Phase 1 trials. Chief executive Dr Huw Jones said: "With final GLP toxicology studies underway and GMP manufacture complete for bulk material, we are approaching more value inflection points ahead of first-in-human trials." On 30 September 2026, the company posted its Annual Report and said the programme is "fully funded through final pre-clinical trials to clinical readiness", with first-in-man regulatory submissions targeted for 2026. Its Annual General Meeting is scheduled for 22 October 2026.

Financial position and funding

The company reported a post-tax loss of £3.5m (FY2025: £1.9m), with R&D spending of £1.5m, up £1.2m. Cash at 31 March 2026 was £1.5m, after an operating cash outflow of £2.7m. In September 2026, it completed a £1.05m fundraising at 0.18p per share, comprising 416,388,888 placing shares and 166,944,440 subscription shares, which it said extends its cash runway to the first quarter of 2027.

The auditors noted a material uncertainty over going concern, reflecting the need for additional funding beyond twelve months, with no binding arrangements in place when the accounts were approved. Earlier in the year, the board rejected a non-binding proposal to acquire the Ox-1 and DAT programmes, saying it placed far too low a value on the company's technology and future commercial potential.

Risks and milestones to watch

Drug development carries high failure rates at every stage, including early clinical trials, and positive preclinical safety data do not ensure success in humans. Regulatory and ethics approvals in Australia may take longer than planned. The funding position is tight: a runway into early 2027 means further Capital or a partnering deal will likely be needed to run clinical trials, and new share issues at low prices can significantly dilute existing holders. The outcome of partnering talks, the completion of toxicology studies and the timing of the Australian submissions are the key items. Any update at the October AGM on partnering or funding would also be relevant, given the runway the company has set out.

How the company is preparing for trials

On its own account, TheraCryf has completed GMP manufacture of clinical material, is finishing GLP toxicology and is preparing Australian regulatory and ethics filings, funded by its recent raise. Clinical entry now depends on those submissions proceeding and on securing longer-term finance.